Monitoring the safety of COVID-19 vaccines in pregnancy in the US

Hum Vaccin Immunother. 2021 Dec 2;17(12):4705-4713. doi: 10.1080/21645515.2021.1984132. Epub 2021 Nov 10.

Abstract

Pregnant persons are at increased risk of severe illness from COVID-19. The first COVID-19 vaccines in the U.S. were authorized for emergency use in December 2020 and pregnant persons were eligible and could get vaccinated despite scarce safety data in this population. To monitor the safety of COVID-19 vaccination during pregnancy, four surveillance systems are used by the Centers for Disease Control and Prevention (CDC). The Vaccine Adverse Event Reporting System is a national, passive system that captures reports of potential adverse events. V-safe is a novel, active system that uses text messaging and web-based surveys to provide health check-ins after vaccination; and enrolls eligible v-safe participants in the v-safe pregnancy registry. The Vaccine Safety Datalink is a collaboration between the CDC and nine integrated health care organizations which performs near-real time surveillance and traditional epidemiologic studies on pregnant vaccine recipients. The CDC is committed to timely and comprehensive monitoring of COVID-19 vaccine safety in pregnancy.

Keywords: Adverse events; COVID-19; SARS-COV-2; adenovirus type 26; coronavirus; epidemiology; mRNA vaccines; pregnancy; surveillance; vaccine safety.

MeSH terms

  • COVID-19 Vaccines / adverse effects
  • COVID-19* / prevention & control
  • Female
  • Humans
  • Pregnancy
  • SARS-CoV-2
  • Vaccination
  • Vaccines*

Substances

  • COVID-19 Vaccines
  • Vaccines

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.